Singapore markets close in 2 hours 45 minutes

AbbVie Inc. (ABBV)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
167.29-0.51 (-0.30%)
At close: 04:00PM EDT
166.19 -1.10 (-0.66%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close167.80
Open167.66
Bid0.00 x 800
Ask0.00 x 800
Day's range165.57 - 169.29
52-week range130.96 - 182.89
Volume5,447,062
Avg. volume5,630,903
Market cap296.212B
Beta (5Y monthly)0.56
PE ratio (TTM)61.28
EPS (TTM)2.73
Earnings date26 Apr 2024
Forward dividend & yield6.20 (3.71%)
Ex-dividend date12 Apr 2024
1y target est184.70
  • Reuters

    Cigna to offer Humira rivals with $0 copay at specialty pharmacy

    Cigna plans to make close copies of AbbVie's blockbuster arthritis drug Humira available with no out-of-pocket payment to eligible patients in the U.S. using its specialty pharmacy beginning in June, the health insurer said on Thursday. Cigna said it will stock high- and low-concentration biosimilar versions of Humira from drugmakers including Boehringer Ingelheim, Teva and Alvotech at its Accredo pharmacy.

  • Reuters

    UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study

    AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to-head study. Rinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a no-to-little itch after 16 weeks of treatment, compared with 8.9% of patients treated with Dupixent, the study showed. The study is the first head-to-head trial in adults and adolescents with moderate-to-severe atopic dermatitis and had shown an inadequate response to systemic therapy, AbbVie said.

  • Zacks

    Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie

    Eli Lilly, Novo Nordisk, Merck and AbbVie are part of the Zacks Industry Outlook article.